Why Did Bill Ackman Buy Alphabet Stock?
Bill Ackman has become famous in the investing world for…
Sell
46
BDRX Quote, Financials, Valuation and Earnings
Last price:
$1.55
Seasonality move
:
-7.56%
Day range:
$1.52 - $1.65
52-week range:
$1.14 - $74.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.61x
P/B ratio:
0.38x
Volume:
152.9K
Avg. volume:
2.2M
1-year change:
-91.45%
Market cap:
$4M
Revenue:
$474.1K
EPS (TTM):
-$74.60
Analysts' Opinion
-
Consensus RatingBiodexa Pharmaceuticals PLC has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $17.94, Biodexa Pharmaceuticals PLC has an estimated upside of 1057.67% from its current price of $1.55.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $17.94 representing 100% downside risk from its current price of $1.55.
Fair Value
-
According to the consensus of 1 analyst, Biodexa Pharmaceuticals PLC has 1057.67% upside to fair value with a price target of $17.94 per share.
BDRX vs. S&P 500
-
Over the past 5 trading days, Biodexa Pharmaceuticals PLC has overperformed the S&P 500 by 3.63% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Biodexa Pharmaceuticals PLC does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Biodexa Pharmaceuticals PLC has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Biodexa Pharmaceuticals PLC reported revenues of --.
Earnings Growth
-
Biodexa Pharmaceuticals PLC has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Biodexa Pharmaceuticals PLC reported earnings per share of --.
Enterprise value:
1.9M
EV / Invested capital:
--
Price / LTM sales:
1.61x
EV / EBIT:
--
EV / Revenue:
3.94x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.11x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$4.9M
Return On Assets:
-87.8%
Net Income Margin (TTM):
-1854%
Return On Equity:
-160.77%
Return On Invested Capital:
-160.77%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2017-12-31 | 2018-12-31 | |
| Income Statement | ||||||
| Revenue | $2.2M | $1.3M | $2.5M | -- | -- | |
| Gross Profit | -$7.8M | -$9.6M | -$9.9M | -- | -- | |
| Operating Income | -$14M | -$15.3M | -$15.7M | -- | -- | |
| EBITDA | -$6.4M | -$13.4M | -$13.7M | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $12.6M | $15.9M | $5.7M | $9M | $11.1M | |
| Total Assets | $13.4M | $17.4M | $6.7M | $13.4M | $18.5M | |
| Current Liabilities | $4.1M | $2.5M | $2.3M | $7.1M | $6.3M | |
| Total Liabilities | $4.2M | $3.3M | $2.9M | $7.5M | $8.1M | |
| Total Equity | $9.2M | $14.1M | $3.8M | $6M | $10.4M | |
| Total Debt | $145.8K | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-04-28 | 2024-04-28 | 2024-04-28 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
BDRX
Sector
Market Cap
$4M
$35M
Price % of 52-Week High
2.1%
44.47%
Dividend Yield
0%
0%
Shareholder Yield
-163.2%
-0.9%
1-Year Price Total Return
-91.45%
-38.53%
Beta (5-Year)
1.705
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.46
200-day SMA
Sell
Level
$7.10
Bollinger Bands (100)
Sell
Level
2.03 - 4.73
Chaikin Money Flow
Sell
Level
-65.3M
20-day SMA
Buy
Level
$1.48
Relative Strength Index (RSI14)
Sell
Level
43.94
ADX Line
Buy
Level
8.41
Williams %R
Neutral
Level
-50.7614
50-day SMA
Sell
Level
$2.29
MACD (12, 26)
Sell
Level
-0.20
25-day Aroon Oscillator
Sell
Level
-24
On Balance Volume
Neutral
Level
75.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-20.6595)
Sell
CA Score
(Annual)
Level (-4.661)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (6.9391)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
Stock Forecast FAQ
In the current month, BDRX has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BDRX average analyst price target in the past 3 months is $17.94.
-
Where Will Biodexa Pharmaceuticals PLC Stock Be In 1 Year?
According to analysts, the consensus estimate is that Biodexa Pharmaceuticals PLC share price will rise to $17.94 per share over the next 12 months.
-
What Do Analysts Say About Biodexa Pharmaceuticals PLC?
Analysts are divided on their view about Biodexa Pharmaceuticals PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Biodexa Pharmaceuticals PLC is a Sell and believe this share price will drop from its current level to $17.94.
-
What Is Biodexa Pharmaceuticals PLC's Price Target?
The price target for Biodexa Pharmaceuticals PLC over the next 1-year time period is forecast to be $17.94 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BDRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Biodexa Pharmaceuticals PLC is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of BDRX?
You can purchase shares of Biodexa Pharmaceuticals PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Biodexa Pharmaceuticals PLC shares.
-
What Is The Biodexa Pharmaceuticals PLC Share Price Today?
Biodexa Pharmaceuticals PLC was last trading at $1.55 per share. This represents the most recent stock quote for Biodexa Pharmaceuticals PLC. Yesterday, Biodexa Pharmaceuticals PLC closed at $1.55 per share.
-
How To Buy Biodexa Pharmaceuticals PLC Stock Online?
In order to purchase Biodexa Pharmaceuticals PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Bill Ackman Buy Brookfield Stock?
Bill Ackman of Pershing Square Capital has made a number…
Why Is Chewy Stock Up — And Will It Keep Climbing?
We are all witnesses to the crazy e-commerce industry boom…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
27
SAIA alert for Apr 26
Saia [SAIA] is down 30.77% over the past day.
Sell
48
APPF alert for Apr 26
AppFolio [APPF] is down 18.16% over the past day.
Sell
15
KNSL alert for Apr 26
Kinsale Capital Group [KNSL] is down 16.33% over the past day.
